656257-43-1

Basic information

• Product Name: 1-(4-BroMophenyl)-4-ethylpiperazine
• Synonyms: 1-(4-BroMophenyl)-4-ethylpiperazine
• CAS NO: 656257-43-1
• Molecular Formula: C₁₂H₁₇BrN₂
• Molecular Weight: 269.18078
• Mol File: 656257-43-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-BroMophenyl)-4-ethylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMophenyl)-4-ethylpiperazine(656257-43-1)
• EPA Substance Registry System: 1-(4-BroMophenyl)-4-ethylpiperazine(656257-43-1)

Safety Data

• Hazardous Substances Data: 656257-43-1(Hazardous Substances Data)

Usage

Chemical structure

Piperazine derivative with a bromophenyl group attached to the nitrogen atom and an ethyl group attached to one of the carbon atoms in the piperazine ring.

Usage

Pharmaceutical intermediate

Therapeutic potential

Anti-inflammatory, antioxidant, and neuroprotective properties

Synthesis

Used in the synthesis of various pharmaceuticals and research chemicals

Hazardous nature

Potentially hazardous chemical that may cause skin and eye irritation

Safety precautions

Should only be used by trained professionals in a controlled laboratory environment

Upstream product

• 57498-25-6 N-phenyl-N′-ethylpiperazine 
• 678996-43-5 1-acetyl-4-(4-bromo-phenyl)-piperazine 
• 5308-25-8 4-ethylpiperazine 
• 589-87-7 1,4-bromoiodobenzene 
• 66698-28-0 1-(4-bromophenyl)piperazine 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 

Downstream Products

• 656257-45-3 1-ethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine 

Relevant articles and documents

CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS

The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cance

NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS

Derivatives of N,N-diethyl-N'- phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

AROMATIC COMPOUND

An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.